Autophagy: Friend or Foe in Lung Disease?

被引:69
|
作者
Mizumura, Kenji [1 ,2 ]
Cloonan, Suzanne [2 ]
Choi, Mary E. [2 ]
Hashimoto, Shu [1 ]
Nakahira, Kiichi [2 ]
Ryter, Stefan W. [2 ]
Choi, Augustine M. K. [2 ]
机构
[1] Nihon Univ, Div Resp Med, Sch Med, Tokyo, Japan
[2] Weill Cornell Med Coll, New York Presbyterian Hosp, Joan & Sanford I Weill Dept Med, New York, NY 10065 USA
关键词
autophagy; ciliophagy; inflammasome; mitophagy; necroptosis; CELL-DEATH; INSUFFICIENT AUTOPHAGY; PULMONARY; SENESCENCE; NECROPTOSIS; MITOPHAGY; APOPTOSIS; COPD; PATHOGENESIS; INHIBITION;
D O I
10.1513/AnnalsATS.201507-450MG
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Autophagy is a highly conserved process by which cells can recycle organelles and proteins by degrading them in the lysosomes. Although autophagy is considered a dynamic system responsible for cellular renovation and homeostasis under physiological conditions, it is increasingly clear that autophagy is directly relevant to clinical disease. During disease progression, autophagy not only serves as a cellular protective mechanism but also can represent a harmful event under certain conditions. In addition, although autophagy can act as a nonselective bulk degradation process, recent research shows that autophagy can selectively degrade specific proteins, organelles, and invading bacteria, in processes termed "selective autophagy." Selective autophagy has drawn the attention of researchers because of its potential importance in clinical diseases. In this article, we outline the most recent studies implicating autophagy and selective autophagy in human lung diseases, including chronic obstructive pulmonary disease, pulmonary hypertension, idiopathic pulmonary fibrosis, and sepsis. We also discuss the relationship between autophagy and other molecular mechanisms related to disease progression, including programmed necrosis (necroptosis) and the inflammasome, an inflammatory signaling platform that regulates the secretion of IL-1 beta and IL-18. Finally, we examine the dual nature of autophagy and selective autophagy in the lung, which have both protective and injurious effects for human lung disease.
引用
收藏
页码:S40 / S47
页数:8
相关论文
共 50 条
  • [31] Woven Coronary Disease Friend or Foe?
    Cito, Salvatore
    Puri, Rishi
    Pallares, Jordi
    Abdul-Jawad Altisent, Omar
    Bayes-Genis, Antoni
    CIRCULATION-CARDIOVASCULAR INTERVENTIONS, 2019, 12 (09)
  • [32] Osteopontin in Vascular Disease Friend or Foe?
    Lok, Zoe Shin Yee
    Lyle, Alicia N.
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2019, 39 (04) : 613 - 622
  • [33] Statins and Renal Disease: Friend or Foe?
    Deshmukh, Abhishek
    Mehta, Jawahar L.
    CURRENT ATHEROSCLEROSIS REPORTS, 2011, 13 (01) : 57 - 63
  • [34] The lung's friend, the gut's foe
    Hildebrandt, Gerhard
    BLOOD, 2007, 110 (03) : 792 - 793
  • [35] Thioredoxin: friend or foe in human disease?
    Burke-Gaffney, A
    Callister, MEJ
    Nakamura, H
    TRENDS IN PHARMACOLOGICAL SCIENCES, 2005, 26 (08) : 398 - 404
  • [36] Asthma disease management: Friend or foe?
    Kennerly, D
    ALLERGY AND ASTHMA PROCEEDINGS, 1999, 20 (05) : 293 - 298
  • [37] Extrapericardial fat: friend or foe in lung transplantation
    Chow, Bobby Hiu Nam
    Dimarakis, Ioannis
    BMJ CASE REPORTS, 2022, 15 (11)
  • [38] Statins and Renal Disease: Friend or Foe?
    Abhishek Deshmukh
    Jawahar L. Mehta
    Current Atherosclerosis Reports, 2011, 13 : 57 - 63
  • [39] microRNAs in mycobacterial disease: friend or foe?
    Mehta, Manali D.
    Liu, Philip T.
    FRONTIERS IN GENETICS, 2014, 5
  • [40] Autophagy in Renal Ischemia-Reperfusion Injury: Friend or Foe?
    Decuypere, J. -P.
    Pirenne, J.
    Jochmans, I.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2014, 14 (06) : 1464 - 1465